Clinical Trial Update: A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 study comparing sotorasib with durvalumab in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• LUMAKRAS (sotorasib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED